MDS

Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs

Thursday, August 5, 2021 - 10:00pm

The Companys lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors.

Key Points: 
  • The Companys lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors.
  • APR-548, a next generation small molecule reactivator of mutant p53, is being developed for oral administration.
  • The p53 tumor suppressor gene is the most frequently mutated gene in human cancer, occurring in approximately 50% of all human tumors.
  • Apreas myeloid malignancy program consists of clinical trials in frontline MDS, AML and post-transplant maintenance therapy in MDS/AML.

Syros Reports Second Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Thursday, August 5, 2021 - 12:30pm

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2021, and provided an update on recent accomplishments and upcoming events.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2021, and provided an update on recent accomplishments and upcoming events.
  • Research and development expenses were $25.8 million for the first quarter of 2021, as compared to $14.8 million for the second quarter of 2020.
  • General and administrative (G&A) expenses were $5.5 million for the second quarter of 2021, as compared to $5.1 million for the second quarter of 2020.
  • ET to discuss these second quarter 2021 financial results and provide a corporate update.

Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights

Wednesday, August 4, 2021 - 9:01pm

This is an exciting time in our Companys history as we plan for a steady stream of milestones in the second half of 2021, commented Filippo Petti, Chief Executive Officer of Celyad Oncology.

Key Points: 
  • This is an exciting time in our Companys history as we plan for a steady stream of milestones in the second half of 2021, commented Filippo Petti, Chief Executive Officer of Celyad Oncology.
  • Research & Development Day held on July 20, 2021, during which the management team provided:
    Updates on the allogeneic CAR T clinical candidates CYAD-211 and CYAD-101.
  • Report additional data from the dose-escalation Phase 1 CYCLE-1 trial evaluating CYAD-02 in r/r AML and MDS by year-end 2021.
  • Key financial figures for the first half of 2021, compared with the first half of 2020 and full year 2020, are summarized below:

Adventech, LLC Releases More Remarkable Maxeff Motor Testing Results

Monday, August 2, 2021 - 11:00am

FLORENCE, Ala., Aug. 2, 2021 /PRNewswire/ --Shoals-based industrial technology solutions provider, Adventech, LLC, todayannounced the positive results of independent verification testing of the company's Maxeff InductionMotorGenerator.

Key Points: 
  • FLORENCE, Ala., Aug. 2, 2021 /PRNewswire/ --Shoals-based industrial technology solutions provider, Adventech, LLC, todayannounced the positive results of independent verification testing of the company's Maxeff InductionMotorGenerator.
  • The published verification data was the result of June 2021 testing conducted by NVLAP-accredited,independent testing team MDS.
  • "Adventech is a proven efficiency market leader with over 3500 motors globally in service, real validationcomes from the results our customers experience."
  • Formore information about Adventech, LLC and the Maxeff motor generator, contact Kasidhe Pruet at256.712.5783orbyemailatsales@adventechinc.com

RIMES’ transformational new Lean Data Management solution wins at the Waters Rankings and HFM European Technology Awards

Thursday, July 22, 2021 - 4:59pm

RIMES newly launched Lean Data Management solution powered by Managed Data Services (MDS) has already won two leading industry awards since it launched in April this year.

Key Points: 
  • RIMES newly launched Lean Data Management solution powered by Managed Data Services (MDS) has already won two leading industry awards since it launched in April this year.
  • The new service from the global leader in managed data services for financial institutions has been named a winner at both the Waters Rankings 2021 and the HFM European Technology Awards 2021.
  • This is the companys first Waters Ranking, reflecting the impact MDS Lean Data Management is having on the industry and showcases RIMES as a strategic data partner to financial institutions.
  • RIMES Lean Data Management powered by MDS is a flexible, cloud-based, service-led approach that redefines data operations for the financial services sector.

Worldwide Myelodysplastic Syndrome Treatment Drugs Industry to 2029 - by Drug Class and Geography - ResearchAndMarkets.com

Wednesday, June 16, 2021 - 3:13pm

North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2019 - 2029 (US$ Mn)

Key Points: 
  • North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2019 - 2029 (US$ Mn)
    6.2.2.
  • Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2019 - 2029 (US$ Mn)
    6.3.2.
  • Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2019 - 2029 (US$ Mn)
    6.4.2.
  • Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2019 - 2029 (US$ Mn)
    6.5.2.

Brad Hunt Appointed RIMES CEO to Drive the Company’s Lean Data Management Innovation Strategy

Thursday, June 3, 2021 - 8:02pm

RIMES , the global leader in Managed Data Services (MDS) for financial institutions, today announces that Brad Hunt has been appointed CEO.

Key Points: 
  • RIMES , the global leader in Managed Data Services (MDS) for financial institutions, today announces that Brad Hunt has been appointed CEO.
  • The appointment comes as the business accelerates the development of its innovative data management solutions for the asset management industry.
  • Brad will lead RIMES in expanding its Lean Data Management (LDM) approach to Managed Data Services (MDS) following the launch of the companys cloud-based data management solution in April 2021 .
  • This will include RIMES new Lean Data Management service, a flexible, cloud-based, service-led approach that redefines data operations for the financial services sector.

Shawmut Corporation Partners With The Massachusetts Dental Society to Provide Members With US-Made PPE

Tuesday, May 4, 2021 - 2:00pm

b'WEST BRIDGEWATER, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Shawmut Corporation today announced a partnership with the Massachusetts Dental Society (MDS) to offer its 5,000+ members PPE as part of the organization\xe2\x80\x99s Member Savings Program.

Key Points: 
  • b'WEST BRIDGEWATER, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Shawmut Corporation today announced a partnership with the Massachusetts Dental Society (MDS) to offer its 5,000+ members PPE as part of the organization\xe2\x80\x99s Member Savings Program.
  • \xe2\x80\x9cWhen we heard of the many struggles MDS members experienced sourcing quality, reliable PPE, we wanted to help ensure our fellow Bay Staters had the equipment needed to provide their services through the pandemic and beyond safely.
  • We are proud to partner with the Massachusetts Dental Society to ensure its members will always have a reliable resource for high-quality, US-made PPE going forward.
  • Shawmut Corporation is based in West Bridgewater, Mass., and can be found online on LinkedIn , Facebook and, Instagram .

Aetina Announce New Multi-Display Series to Next Vision Era

Thursday, December 10, 2020 - 7:30am

TAIPEI, Dec. 10, 2020 /PRNewswire/ -- Aetina Corporation, an expert in the GPU application field, announce their brand-new position of multi-display solution.

Key Points: 
  • TAIPEI, Dec. 10, 2020 /PRNewswire/ -- Aetina Corporation, an expert in the GPU application field, announce their brand-new position of multi-display solution.
  • Their products, including the series of Multi Displays Savant (MDS) and Multi Monitors Marvel (M3) for the new position outlines.
  • Aetina Multi-Display Series brings the superior power of the latest GPU computing performance with best-in-class picture quality.
  • It also helps the business deliver content professionally and attractively by providing exceptional durability solution in the next vision generation.

Canadian Agency MDS Media Inc. Ranks Top 5 in the World and Takes Home International Honors Against Major Ad Agencies

Friday, November 13, 2020 - 9:45pm

Launched in 2018, the video marketing firm prides itself on its unique creative models and content strategy.

Key Points: 
  • Launched in 2018, the video marketing firm prides itself on its unique creative models and content strategy.
  • The MDS Media videos brought home numerous awards from their arsenal of media work with various technology companies.
  • "As importantly, the honors also give us a more credible position at a crucial time in the competitive landscape.
  • For more information about MDS Media Inc. go to http://www.mds.media or contact them at info@mds.media